These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
208 related articles for article (PubMed ID: 33389670)
1. Membranous nephropathy with thrombotic microangiopathy-like lesions successfully treated with tocilizumab in a patient with idiopathic multicentric Castleman disease. Tosaki T; Okabe M; Suzuki T; Shimizu A; Koike K; Tsuboi N; Kawamura T; Ohashi R; Yano S; Yokoo T CEN Case Rep; 2021 May; 10(2):265-272. PubMed ID: 33389670 [TBL] [Abstract][Full Text] [Related]
2. Two cases of idiopathic multicentric Castleman disease with nephrotic syndrome treated with tocilizumab. Furutera N; Fukunaga N; Okita J; Suzuki T; Suenaga Y; Oyama Y; Aoki K; Fukuda A; Nakata T; Uesugi N; Daa T; Hisano S; Shibata H CEN Case Rep; 2021 Feb; 10(1):35-41. PubMed ID: 32715375 [TBL] [Abstract][Full Text] [Related]
3. Idiopathic multicentric Castleman disease with Sjögren's syndrome and secondary membranous nephropathy: a case report and review of the literature. Pan Y; Cui Z; Wang S; Zheng D; Deng Z; Tian X; Guo H; Bao W; Zhou S; Wang Y BMC Nephrol; 2020 Dec; 21(1):528. PubMed ID: 33276741 [TBL] [Abstract][Full Text] [Related]
4. Membranous nephropathy associated with multicentric Castleman's disease that was successfully treated with tocilizumab: a case report and review of the literature. Saiki R; Katayama K; Hirabayashi Y; Oda K; Fujimoto M; Murata T; Nakajima A; Dohi K BMC Nephrol; 2021 Jun; 22(1):216. PubMed ID: 34107915 [TBL] [Abstract][Full Text] [Related]
5. Case report: Importance of early and continuous tocilizumab therapy in nephrotic syndrome associated with idiopathic multicentric Castleman disease: A case series. Kojima D; Yamaguchi S; Hashiguchi A; Hayashi K; Uchiyama K; Yoshimoto N; Adachi K; Nakayama T; Nishioka K; Tajima T; Morimoto K; Yoshino J; Yoshida T; Monkawa T; Kanda T; Itoh H Front Med (Lausanne); 2022; 9():1037032. PubMed ID: 36698794 [TBL] [Abstract][Full Text] [Related]
6. Idiopathic Multicentric Castleman Disease with Autoimmune Hemolytic Anemia and Production of Anti-drug Antibody against Tocilizumab. Tabata S; Higuchi T; Tatsukawa S; Narimatsu K; Takeo H; Matsukuma S; Ito T Intern Med; 2019 Nov; 58(22):3313-3318. PubMed ID: 31292389 [TBL] [Abstract][Full Text] [Related]
7. Renal Pathologic Findings in TAFRO Syndrome: Is There a Continuum Between Thrombotic Microangiopathy and Membranoproliferative Glomerulonephritis? A Case Report and Literature Review. Leurs A; Gnemmi V; Lionet A; Renaud L; Gibier JB; Copin MC; Hachulla E; Hatron PY; Launay D; Fajgenbaum D; Terriou L Front Immunol; 2019; 10():1489. PubMed ID: 31316523 [No Abstract] [Full Text] [Related]
8. Successful treatment with tocilizumab for refractory anemia and slowly progressive renal glomerulosclerosis in multicentric Castleman disease: A case report. Sugawara E; Sato T; Amasaki Y; Katsumata K Medicine (Baltimore); 2022 Feb; 101(8):e28941. PubMed ID: 35212301 [TBL] [Abstract][Full Text] [Related]
9. Successful treatment of TAFRO syndrome, a variant type of multicentric Castleman disease with thrombotic microangiopathy, with anti-IL-6 receptor antibody and steroids. Fujiwara S; Mochinaga H; Nakata H; Ohshima K; Matsumoto M; Uchiba M; Mikami Y; Hata H; Okuno Y; Mitsuya H; Nosaka K Int J Hematol; 2016 Jun; 103(6):718-23. PubMed ID: 26980221 [TBL] [Abstract][Full Text] [Related]
10. Kidney biopsy findings in two patients with TAFRO syndrome: case presentations and review of the literature. Zhou Q; Zhang Y; Zhou G; Zhu J BMC Nephrol; 2020 Nov; 21(1):499. PubMed ID: 33225930 [TBL] [Abstract][Full Text] [Related]
11. TAFRO Syndrome with Renal Thrombotic Microangiopathy: Insights into the Molecular Mechanism and Treatment Opportunities. Tu KH; Fan PY; Chen TD; Chuang WY; Wu CY; Ku CL; Tian YC; Yang CW; Fang JT; Yang HY Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34208103 [TBL] [Abstract][Full Text] [Related]
12. TAFRO syndrome as a cause of glomerular microangiopathy: a case report and literature review. Nagayama Y; Yamano M; Yagame M; Nariyama T; Takahashi M; Kawamoto M; Matsui K BMC Nephrol; 2019 Oct; 20(1):375. PubMed ID: 31623576 [TBL] [Abstract][Full Text] [Related]
13. Tocilizumab histologically improved AA renal amyloidosis in a patient with multicentric Castleman disease: A case report . Yamada Y; Ueno T; Irifuku T; Nakashima A; Doi S; Ichinohe T; Masaki T Clin Nephrol; 2018 Sep; 90(3):232-236. PubMed ID: 29701172 [TBL] [Abstract][Full Text] [Related]
14. [Thrombotic microangiopathy developing subsequent to tocilizumab therapy in a patient with TAFRO syndrome]. Ito S; Tsutsumi Y; Kikuchi R; Matsuoka S; Shimoyama N Rinsho Ketsueki; 2018; 59(11):2432-2437. PubMed ID: 30531139 [TBL] [Abstract][Full Text] [Related]
15. [Evans syndrome complicated with multicentric Castleman disease successfully treated with tocilizumab]. Nakayama H; Kikuchi T; Abe R; Tozawa K; Watanuki S; Shimizu T; Mitsuhashi T; Murata M; Okamoto S; Mori T Rinsho Ketsueki; 2018; 59(8):997-1001. PubMed ID: 30185717 [TBL] [Abstract][Full Text] [Related]
16. Schnitzler syndrome co-occurring with idiopathic multicentric Castleman disease that responds to anti-IL-1 therapy: A case report and clue to pathophysiology. Soudet S; Fajgenbaum D; Delattre C; Forestier A; Hachulla E; Hatron PY; Launay D; Terriou L Curr Res Transl Med; 2018 Sep; 66(3):83-86. PubMed ID: 30108026 [TBL] [Abstract][Full Text] [Related]
17. Idiopathic multicentric Castleman disease treated with siltuximab for 15 years: a case report. Lang E; Sande B; Brodkin S; van Rhee F Ther Adv Hematol; 2022; 13():20406207221082552. PubMed ID: 35251585 [TBL] [Abstract][Full Text] [Related]
18. Idiopathic multicentric Castleman disease preceded by cutaneous plasmacytosis successfully treated by tocilizumab. Aita T; Hamaguchi S; Shimotani Y; Nakamoto Y BMJ Case Rep; 2020 Nov; 13(11):. PubMed ID: 33148595 [TBL] [Abstract][Full Text] [Related]
19. A Case of the nephrotic syndrome in bone marrow transplantation recipient, histologically showing overlapped glomerular lesions of thrombotic microangiopathy and membranous nephropathy. Masuzawa N; Nishimura A; Kitani T; Tamagaki K; Sugitani M; Nagoshi H; Kuroda J; Konishi E Pathol Int; 2017 Dec; 67(12):620-625. PubMed ID: 28940837 [TBL] [Abstract][Full Text] [Related]
20. Psoas and Mediastinal Abscesses during Intravenous Tocilizumab Treatment in Multicentric Castleman Disease. Togitani K; Ogasawara F; Arakawa Y; Sugimura N; Miyazaki R; Kojima K Intern Med; 2023 Feb; 62(3):449-452. PubMed ID: 35732449 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]